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Abstract
Nontypeable Haemophilus influenzae (NTHi) is an opportunistic pathogen that is a common cause of acute and recurrent
mucosal infections. One uncharacterized NTHi toxin-antitoxin (TA) module, NTHI1912-1913, is a host inhibition of growth
(higBA) homologue. We hypothesized that this locus, which we designated toxAvapA, contributed to NTHi survival during
infection. We deleted toxAvapA and determined that growth of the mutant in defined media was not different from the
parent strain. We tested the mutant for persistence during long-term in vitro co-culture with primary human respiratory
tissues, which revealed that the DtoxAvapA mutant was attenuated for survival. We then performed challenge studies using
the chinchilla model of otitis media and determined that mutant survival was also reduced in vivo. Following purification,
the toxin exhibited ribonuclease activity on RNA in vitro, while the antitoxin did not. A microarray comparison of the
transcriptome revealed that the tryptophan biosynthetic regulon was significantly repressed in the mutant compared to the
parent strain. HPLC studies of conditioned medium confirmed that there was no significant difference in the concentration
of tryptophan remaining in the supernatant, indicating that the uptake of tryptophan by the mutant was not affected. We
conclude that the role of the NTHi toxAvapA TA module in persistence following stress is multifactorial and includes effects
on essential metabolic pathways.
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Introduction
Nontypeable Haemophilus influenzae (NTHi) are pleomorphic
Gram-negative bacteria that reside in the human upper respira-
tory tract as commensals. However, these organisms are also
responsible for a number of mucosal diseases, including chronic
bronchitis, exacerbations of chronic obstructive pulmonary
disease, and acute and chronic otitis media (OM). Recurrent
OM caused by NTHi is common, and those infections that recur
less than two weeks after the completion of antimicrobial therapy
have been shown to largely be due to the same strain of bacteria,
suggesting a subpopulation of persister cells [1,2]. Toxin-antitoxin
(TA) gene pairs have been found in nearly all bacterial genomes
sequenced to date, and type II loci encode a protein toxin and
antitoxin that form a nontoxic complex upon translation which
auto-represses the cognate promoter [3]. Under stressful environ-
mental conditions such as nutrient limitation, antibiotic therapy,
or oxidative stress, the labile antitoxin is degraded by intracellular
proteases and the more stable toxin is freed to facilitate growth
arrest, often via mRNA degradation [4,5]. The ability to induce a
state of dormancy increases microbial fitness by decreasing
nutrient requirements and the metabolic burden. As well, this
persister state facilitates nonspecific antibiotic tolerance in the
microorganism, as most antimicrobials target essential cellular
functions necessary for bacterial growth and replication [6].
TA modules have been divided into several families, one of
which is the host inhibition of growth (higBA) gene pair [7]. Most
TA operons are organized such that the antitoxin is transcribed
first, followed by the toxin, and the higBA locus is unusual in that
the toxin gene precedes the antitoxin. Originally identified on the
Proteus vulgaris Rts1 plasmid [7], the higBA module has been found
in the chromosomes of a number of pathogens, including Vibrio
cholerae, Mycobacterium tuberculosis, Pseudomonas aeruginosa, Yersinia
pestis, and Acinetobacter baumannii [8–12]. NTHi strains contain three
TA gene pair families, and one of these is a higBA homologue. In
previous work, we have shown that two of the TA loci in NTHi
exert significant effects on the organism’s ability to sustain an
infection, both in vitro and in vivo [13]. In this study, we investigated
the hypothesis that the higBA homologue in the NTHi strain 86-
028NP (NTHI1912-1913, designated toxAvapA), also played a role
in the survival of this human-adapted pathogen. We found that the
toxAvapA locus enhanced the ability of NTHi to persist during in
vitro and in vivo infections.
Materials and Methods
Bacterial Strains and Plasmids
The bacterial strains and plasmids used in these studies are
listed in Table 1. E. coli strains were grown in LB broth or agar
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with or without 30 mg/ml kanamycin or 100 mg/ml ampicillin, as
required. NTHi strains were grown in brain heart infusion
supplemented with 10 mg/ml heme-histidine and 10 mg/ml b-
NAD (sBHI) broth or agar. E. coli strain BL21(DE3) was used to
overexpress toxAvapA for protein purification prior to use in
ribonuclease activity assays. NTHi transformants were selected on
chocolate agar plates with 25 mg/ml spectinomycin, and were
routinely cultured at 37uC with 5% CO2.
Construction of a DtoxAvapA Mutant
The DtoxAvapA mutation construct was assembled by amplifying
genomic DNA (gDNA) from NTHi strain 86-028NP [14] using
Phusion FLASH high fidelity polymerase (Thermo Fisher Scien-
tific, Waltham, MA USA), which results in blunt-ended amplicons,
and primers with engineered restriction sites (underlined)
KpnToxFor (59-AAAAGGTACCGGCGAGTGCAATCAC-39)
and ClaToxRev (59-GATAATCGATTCTAAAATGCTCACG-
39). The 1000 bp PCR product was cut with KpnI and ClaI and
fused with KpnI/ClaI-digested pBluescript SK+, and designated as
pDD849. The second arm of the construct was made by
amplifying 86-028NP gDNA using the primers 86APstFor (59-
TCTACTGCAGCAATGTAATTTGAGC-39) and 86XbaVa-
pARev (59-GTAATCTAGAGAAGATCCAACCAGC-39). The
XbaI-digested 883 bp amplicon was ligated to pDD849 digested
with Smal and XbaI, resulting in pDD851. A 1200 bp product
which contained a spectinomycin resistance cassette was PCR-
amplified from pDD872 using the primer set pUC4 For (59-
TTCGCTATTACGCCAGCTGG-39) and pUC4 Rev (59-
GCCGATTCATTAATGCAGCTG-39), cut with EcoRI and
ligated to pDD851 digested with EcoRI, generating pDD857. A
3083 bp fragment from pDD857 was amplified with KpnToxFor
and 86XbaVapARev primers and used to transform NTHi strain
86-028NP using the M-IV method as previously described by
Herriott et al. [15]. Colonies resistant to 25 mg/ml spectinomycin
were selected and the deletion of toxAvapA was identified by PCR
and verified by DNA sequencing of both strands.
Growth Curves of the DtoxAvapA Mutant and the Parent
Strain
The 86-028NP parent strain or the DtoxAvapA mutant were re-
suspended from sBHI agar plates grown for 18 hours at 37uC in
5% CO2 into fresh defined media [16] at an OD600 of ,0.1, then
200 microliters of each re-suspension was placed in duodecuplicate
into a sterile non-treated flat-bottomed 96 well plate (#351172,
BD Biosciences, Bedford, MA, USA). Empty wells were filled with
200 microliters of sterile water to decrease evaporation, and the
plate was covered with sterile gas permeable sealing film (#9123-
6100, USA Scientific, Ocala, FL, USA). The plate was incubated
for 15 hours with shaking at 35uC in a Multiskan FC spectro-
photometer (ThermoFisher Scientific, Waltham, MA, USA), and
the OD595 was read hourly. Three biological replicates were
performed and analyzed by the repeated measures analysis of
variance (RMANOVA).
NTHi Invasion Assays in the EpiAirway Tissue Model
EpiAirway tissues (MatTek, Ashland, MA USA) were inoculat-
ed with either 106 NTHi strain 86-028NP (n = 6) or DtoxAvapA
mutant (n = 6) suspended in pre-warmed Dulbecco’s phosphate-
buffered saline with calcium and magnesium (DPBS+) in a total
volume of #25 microliters onto the apical surface. Tissues were
incubated at 37uC in 5% CO2 until harvest at day 2, 4, or 8 after
infection. Tissues were maintained by washing the apical surface
with 200 ml of DPBS+ and the basal media was changed using
1 ml of MatTek airway serum-free medium on a daily basis. On
the day of harvest, inserts were washed with DPBS+ three times,
and then 250 ml of RPMI 1640 supplemented with 100 mg/ml
gentamicin (MP Biomedical, Solon, OH USA) was added to the
apical side, with 1 ml added to the basal side to kill any external
cell-associated bacteria. After incubation at 37uC in 5% CO2 for
one hour, each insert was washed three times with DPBS without
calcium and magnesium (DPBS2) and 250 ml of sterile 1%
saponin (Sigma-Aldrich, St. Louis, MO USA) in DPBS2 was
added to the apical surface. The inserts incubated at 37uC with
5% CO2 for 10 minutes. The tissue was then physically disrupted
from the membrane and collected followed by the addition of
250 ml DPBS2 to the apical surface and the remaining tissue was
collected. Total tissue collection was confirmed by microscopy of
the insert. The volume of the collected tissue suspension was
increased to 1 ml with DPBS2. Each sample was then vortexed
vigorously to de-aggregate the cells and serially diluted using sterile
PBS. Aliquots were drop-plated onto chocolate agar plates to
enumerate viable internalized bacteria.
Table 1. Bacterial strains and plasmids used in this study.
Strain Description Source
DH5a F2 W80lacZDM15 D (lacZYA-argF) U169 recA1 endA1 hsdR17 (rK2, mK+) phoA supE44 l– thi-1 gyrA96 relA1 Lab collection
BL21(DE3) F2 ompT hsdSB(rB2, mB2) gal dcm (DE3) NEB
86-028NP Nontypeable Haemophilus influenzae strain isolated from the nasopharynx of a child being treated for
chronic otitis media
[14]
DtoxAvapA Strain 86-028NP with the toxAvapA locus deleted. This work
Plasmid Description Source
pET24b Bacterial vector for expressing polyhistidine-tagged proteins Novagen
pBluescript SK+ Bacterial cloning vector Lab collection
pDD849 pBluescript SK+ with the 59 arm of the toxAvapA plasmid. This work
pDD851 pDD849 with the 39 arm of the toxAvapA plasmid. This work
pDD857 pDD851 with the spectinomycin resistance cassette. This work
pDD912 pET24b with the toxAvapA locus for protein expression. This work
doi:10.1371/journal.pone.0091523.t001
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Survival of NTHi in the Chinchilla Otitis Media Model
Ethics Statement:. Guidelines published in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health were followed for all animal handling and husbandry. The
protocol #A1110011 was approved by the Mercer University
Institutional Animal Care and Use Committee (Animal Welfare
Assurance Number: A3725-01). All surgery was performed under
isoflurane anesthesia, and all efforts were made to minimize
suffering.
Adult female chinchillas (400–600 g) were purchased from a
commercial supplier and allowed to acclimate in the vivarium for
one week prior to bacterial challenge. On the day of challenge,
each animal was examined by otoscopy for signs of middle ear
infection. Both the wild-type and the DtoxAvapA mutant strain from
frozen stocks were plated on chocolate agar and incubated at 37uC
with 5% CO2 for 18 h. Sterile DPBS with 0.1% gelatin (Sigma-
Aldrich, St. Louis, MO USA) (DPBS-G) was inoculated with the
bacteria to a concentration of 1.06104 CFU/ml and 100 ml of this
suspension was loaded into 1 cc syringes. After chinchillas were
anesthetized by isoflurane inhalation, 100 ml (,103 CFU) of
bacteria was injected into the superior bullae of each animal (n = 4
animals with 8 middle ears per challenge strain). On day 4 post-
challenge, chinchillas were humanely euthanized by cardiac
exsanguination and middle ear fluid was collected. Each middle
ear was then washed with 1 ml DPBS-G. The wash fluid was
collected, serially diluted and drop-plated on chocolate agar for
viable bacterial counts after 18 h incubation at 37uC with 5%
CO2.
Histology of the Chinchilla Middle Ear
Chinchilla bullae were dissected and fixed with 10% neutral
buffered formalin for 24 hours at room temperature. The bullae
were then decalcified with 5% formic acid for 48 hours and cut at
the midline in the sagittal plane. Each half was embedded in
paraffin and step sections of the distal portion were mounted onto
slides, stained with hematoxylin-eosin (H&E) and examined to
determine successful establishment of infection.
Total RNA Isolation
Cultures of the wild-type and DtoxAvapA mutant were grown in
35 ml of defined media [16] in baffled flasks at 35uC with shaking.
Once the OD600 reached ,0.4, five ml of culture was added to
5 ml of RNAlater Solution (Ambion, Life Technologies, Grand
Island, NY USA) and stored at 4uC until processed. The
experiment was repeated in triplicate and all repetitions were
processed within 48 hours of collection. Total RNA was isolated
using the ChargeSwitch Total RNA Cell Kit (Invitrogen, Life
Technologies, Grand Island, NY USA) according to the manu-
facturer’s directions, with the modification of a vial change and an
extended DNAse incubation step (30 min at 37uC). Following
purification, the concentration of the total RNA was determined
by a Nanodrop 2000c spectrophotometer (Thermo Scientific Inc.,
Pittsburgh, PA USA) and aliquots were prepared and stored at
280uC. Prior to cDNA synthesis, PCR using an aliquot of total
RNA as the template was performed to confirm that each
preparation was free of contaminating genomic DNA.
Transcriptome Study
The High Capacity cDNA Reverse Transcriptase kit (Applied
Biosystems, Life Technologies, Grand Island, NY USA) was used
to synthesize cDNA from a pool of total RNA that represented
equal concentrations of three independent RNA isolations per
strain. The cDNA reactions were performed in 100 ml aliquots
according to the manufacturer’s directions, with the modification
that the cDNA was treated with RNase A for 30 min at 35uC
following completion of the protocol. The cDNA was then
column-purified using the MinElute kit (Qiagen, Valencia, CA
USA) and the concentration of the cDNA was determined by a
Nanodrop 2000c spectrophotometer. Approximately 2 mg of
cDNA from either the wild-type or the DtoxAvapA mutant was
labeled and hybridized to a custom 4672 K Nimblegen micro-
array by the Florida State University-Nimblegen Microarray
Facility (Tallahassee, FL USA). Data was analyzed using the
ArrayStar Version 5.1.0 build 114 software (DNASTAR Inc.,
Madison, WI USA). Validation of microarray results was done by
qPCR on selected genes using a MiniOpticon real-time thermo-
cycler (Bio-Rad, Hercules, CA USA). Briefly, 25 ml reactions were
prepared with 12.5 ml of 2X Power SYBR Green Master Mix (Life
Technologies, Grand Island, NY USA), 400 nM of each gene-
specific primer set, and 5 ml of a 1:10 dilution of the cDNA used in
the microarray study, as well as an independent replicate
performed as an additional control. Relative expression was
calculated by the comparative Ct method (2
2DDCt) using wild-type
cDNA as the calibrator and the expression of a DNA gyrase
subunit gene, gyrA, as the endogenous control.
High Performance Liquid Chromatography (HPLC) of
Conditioned Medium
HPLC was used to determine the tryptophan concentrations in
conditioned medium from the wild-type and the DtoxAvapA
mutant. Briefly, each strain was inoculated in defined medium at
an OD600 of ,0.1 and grown with shaking at 35uC to an OD600 of
0.4. Five milliliters of each culture was pelleted and the
supernatants were passed through 3 kDa MWCO filters (Vivaspin
500, GE Healthcare, Pittsburgh, PA USA). HPLC was done on
pooled filtrates representing three replicates of each strain using a
Waters model 680 automated gradient controller, two model 510
pumps, a Rheodyne model 7725i manual injector (Waters,
Milford, MA USA) and a Shimadzu model SPD-M10A photodi-
ode array detector (Shimadzu Instrument Co., Columbia, MD
USA). The column was a Sorbax Eclipse AAA column,
150 mm64.6 mm i.d. reversed phase C-18 stainless steel column
containing 3.5 mm size silica particles (Agilent Technologies, Santa
Clara, CA USA). The solvents used were (A) 40 mM NH4H2PO4
solution (10.4 pH) and (B) acetonitrile: methanol, 60:40. All
solvents were HPLC grade. Run conditions were: 95% A:5% B for
8 min; then 80% A: 20% B to 20 min; 75% A: 25% B at 30 min;
95% A: 5% B at 40 min; 100% A at 42 min; and, finally, return
start conditions after 45 min [17]. Flow rates were 0.75 mls/min.
Authentic tryptophan (Sigma Aldrich, St. Louis, MO USA) was
suspended in sterile distilled water at 5 mg/ml. Pre-column
derivatization was done with o-phthaldialdehyde/mercapto-etha-
nol (OPA) (Sigma Aldrich, St. Louis, MO USA). Samples ranging
from 5, 10, 25 or 50 mg of authentic tryptophan were injected into
the HPLC system to determine elution times and spectral
characteristics for this amino acid standard (and distinct from
background peaks due to OPA alone, which were excluded).
Subsequently, samples of conditioned media from NTHi wild-type
and mutant were derivatized, injected into the HPLC and the co-
elution times, spectral characteristics and differences in the
amounts (milli-absorbance units) of the putative sample trypto-
phan peak were determined. To confirm the identity of the elution
times, several samples of the conditioned media also were spiked
with authentic tryptophan.
Tryptophan-specific peaks were collected using a Pharmacia
Frac-100 fraction collector (Amersham Biosciences, Piscataway,
NJ USA), lyophilized in a FreeZone Plus 2.5 L lyophilizer
ToxAvapA Contributes to Survival during Infection
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(Labconco, Kansas City, MO USA) and resuspended in sterile
distilled water. The lyophilized fractions were then assayed by thin
layer chromatography (TLC) using 10620 cm silica gel/TLC
cards (Sigma Aldrich, St. Louis, MO USA) and eluted for 2 h with
n-butanol:acetic acid:water 3:1:1 (by volume). The dried card was
then examined by UV fluorescence at 254 nm and stained with
ninhydrin (0.1 g ninhydrin, 100 ml n-butanol, 0.5 ml acetic acid)
followed by gentle heating. Tryptophan in the fractions was
confirmed by co-elution with the authentic standard.
ToxA and VapA Protein Expression and Purification
The toxAvapA operon from NTHi strain 86-028NP was cloned
into pET24b by amplifying gDNA with the following primer pair,
86ToxBamFor (59-GAGAGGATCCGATGTTTAATT-
TAAAGCG-39) and ASacRev (59-GGCTGAGCTCACATTG-
CAAATGTAG-39). The PCR product was cut with BamHI and
SacI and fused with SacI and BamHI-digested pET24b, generating
pDD912. Following DNA sequencing, the plasmid pDD912 was
transformed into E. coli BL21(DE3) strain and grown in 30 ml of
LB broth supplemented with 30 mg/ml kanamycin with shaking in
baffled flasks at 35uC. When the OD600 reached ,0.4, 1 mM
IPTG was added and the culture was incubated for an additional
3 hours. Ten ml cell pellets were isolated, subjected to 3 freeze/
thaw cycles, resuspended in 5 ml of BugBuster solution (16
BugBuster, 100 mM HEPES, 16 Halt EDTA-free protease
inhibitor, 10 ml DNAse) and rotated at room temperature for 30
minutes. The solution was then sonicated with 1.5 second pulses at
10% power for 12 cycles using a Branson Sonifier (Branson
UltraSonics Co. Ltd, Shanghai, P.R. China) equipped with a
microtip. The resulting lysate contained the ToxAVapA protein
complex. The MagneHisTM protein purification system (Promega
Corp., Madison, WI USA) was used to bind polyhistidine-tagged
VapA with the following modifications. The lysate with the
ToxAVapA complex bound to Ni+ magnetic beads was washed
twice with wash buffer (100 mM HEPES (pH 7.5), 150 mM
NaCl, 10 mM imidazole). The bead pellet was then resuspended
in 200 ml of denaturing buffer (100 mM HEPES (pH 7.5) and
8 M urea) and incubated at room temperature for 15 min on a
rotator. The supernatant was collected and removed, representing
purified denatured ToxA protein. The polyhistidine-tagged VapA
protein was then recovered from the Ni+ beads with denaturing
elution buffer (100 mM HEPES, 8 M urea and 500 mM
imidazole) according to the manufacturer’s protocol. Protein
concentrations of both ToxA and VapA were determined by
Bradford assay and protein isolation was confirmed by SDS-
PAGE followed by staining with GelCode Blue (Thermo Scientific
Inc., Pittsburgh, PA USA).
To re-nature the purified proteins, two hundred microliter
aliquots of denatured ToxA or VapA were placed into individual
Slide-A-LyzerH Mini Dialysis 3,500 Da MWCO tubes (Thermo
Scientific Inc., Pittsburgh, PA USA) and dialyzed for 18 hours at
4uC against 25 ml of either acidic refolding buffer (50 mM Na
acetate (pH 4.0), 100 mM KCl, 200 mM arginine, 50 mM
NDSB-201 (3-(1-Pyridino)-1-propane sulfonate) and 50 mM
NDSB-256 (Dimethylbenzylammonium propane sulfonate) for
ToxA (pI 9.1), or alkaline refolding buffer (50 mM Tris (pH 8.0),
100 mM KCl, 200 mM arginine, 50 mM NDSB-201 (3-(1-
Pyridino)-1-propane sulfonate) and 50 mM NDSB-256 (Dimethyl-
benzylammonium propane sulfonate) for VapA (pI 6.7) [18].
These buffers were then replaced with fresh dialysis buffer
containing 10% glycerol, and dialyzed at 4uC for an additional
4 h. The re-natured proteins were concentrated using 3.0 kDa
MWCO centrifugal filters (Vivaspin 500, GE Healthcare,
Pittsburgh, PA USA) and assayed via the Bradford method to
determine total protein concentration.
RNase Activity Assays
The RNaseAlertH substrate (IDT, Coralville, Iowa USA) was
used to determine re-natured ToxA and VapA RNase activity.
ToxA and VapA were diluted to 0.05 mg/ml in 16 RNaseAlert
proprietary buffer and acclimated to room temperature for
30 min. Eighteen pmol of each protein dilution was added to
25 ml RNaseAlert substrate in triplicate wells of a black clear-
bottomed 96-well plate (Corning #3340, Tewksbury, MA USA)
and incubated at 37uC for 1 h. The negative control was an
identical volume of protein renaturation buffer, and the positive
Figure 1. Growth curve of the DtoxAvapA mutant and parent
strain in defined media. No significant difference was found
between the growth of the parent and mutant strains (n = 3 in
duodecuplicate).
doi:10.1371/journal.pone.0091523.g001
Figure 2. Viable wild-type and DtoxAvapA mutant CFU/ml
recovered from chinchilla middle ears after 4 days of infection.
Asterisks denote outliers; p = 0.01; n = 8 ears.
doi:10.1371/journal.pone.0091523.g002
Table 2. Number of viable gentamicin-resistant internalized
bacteria that survived over time in the EpiAirway human
tissue model (n = 6).
Day CFU/ml WT (±SD) CFU/ml DtoxAvapA (±SD) p value % WT
2 8.9E+05 (1.6E+06) 6.2E+04 (5.9E+04) 0.047 7.0
4 7.3E+05 (4.2E+05) 4.3E+05 (1.3E+05) 0.038 58.9
8 2.5E+06 (1.4E+06) 9.5E+05 (6.8E+05) 0.014 38.2
doi:10.1371/journal.pone.0091523.t002
ToxAvapA Contributes to Survival during Infection
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e91523
control was 18 pmol bovine pancreatic RNase A (Thermo
Scientific Fermentas, Pittsburgh, PA USA). Fluorescence (excita-
tion 485 nm, emission 520 nm) was measured using a FLUOstar
OPTIMA plate reader (BMG Labtech, Ortenberg, Germany).
ToxA Kinetic Studies
To determine the initial reaction progress, increasing amounts
of the RNaseAlert substrate (5, 10, and 12.5 pmol) were incubated
with 18 pmol of renatured ToxA in a final volume of 30
microliters. The reactions were incubated at 37uC in a Mini-
Opticon real-time thermocycler (Bio-Rad, Hercules, CA USA)
and fluorescence was measured every 30 seconds on the
fluorescein (FAM) channel for the first 6 minutes. The time zero
measurement was subtracted from each well. A separate set of
reactions using 5 pmol RNaseAlert substrate and 18 pmol
renatured ToxA were incubated at 37uC in a MiniOpticon and
fluorescence was measured every 30 seconds for 30.5 minutes to
allow the reaction to approach completion.
Data Analysis
All data are presented as the mean 6 standard deviation. The
significance of any differences between means was determined
using Student’s t test, analysis of variance (ANOVA) followed by
the Tukey-Kramer test, or repeated measures ANOVA (RMA-
NOVA). A p value of #0.05 was considered statistically significant.
Results and Discussion
Growth Dynamics in Defined Media
We deleted the entire toxAvapA operon in NTHi strain 86-
028NP, and following confirmation of the deletion, we performed
growth curves in defined media to determine whether there were
any growth defects in the DtoxAvapA mutant as compared to the
parent strain. We found that there were no significant differences
by repeated measures ANOVA between the growth of the wild-
type versus the mutant over a 15 hour time period in defined
media (Figure 1). These data suggest that any observed differences
in survival of the mutant in vitro or in vivo would not be attributable
to a fundamental reduction in the organism’s ability to replicate
over the growth cycle.
Co-culture in Primary Human Tissues
NTHi normally reside in the human upper respiratory tract in
close association with the respiratory epithelium. To determine
any effects of the toxAvapA deletion on the ability of NTHi to
survive during long-term co-culture with primary human respira-
tory epithelial tissues, we used the EpiAirwayTM model (MatTek,
Ashland, MA USA). These 3-dimensional, highly differentiated
tissues from normal human donors are metabolically and
mitotically active and have the capacity to survive at the air-
liquid interface for weeks. Further, the proprietary media supplied
with the tissues is serum-free. This allowed us to perform long-
term co-culture of these tissues with both the wild-type and the
DtoxAvapA mutant. We inoculated tissues with ,1.06106 CFU of
each strain, and at days 2, 4, and 8 post-infection, we recovered
the viable gentamicin-resistant (internalized) bacteria that persisted
within the tissues over time (Table 2).
In all cases, the DtoxAvapA mutant was attenuated for survival
compared to the parent strain. This trend was significant at all
time points, but the observed effect of the toxAvapA deletion was
most substantial at the first harvest (2 days post-inoculation), at
which only 7.0% of the wild-type numbers were recovered. This
percentage increased at day 4 to 58.9% but declined again by day
8 to 38.2%, indicating that the mutant was unable to survive at the
levels of the wild-type strain over the entire experimental period.
This is the first report, to our knowledge, of the contribution of
toxAvapA to the survival of NTHi in primary human tissues.
Figure 3. Gross otoscopic view of the tympanic membrane of a chinchilla. The same animal imaged (A) before infection; and (B) 4 days after
inoculation with the DtoxAvapA mutant. Edema and redness indicate a productive infection.
doi:10.1371/journal.pone.0091523.g003
Figure 4. H&E-stained sections of chinchilla middle ears (4006magnification). A. Middle ear mucosa of an uninfected control animal. B.
The middle ear of an animal infected with the DtoxAvapA mutant for 4 days. Note the characteristic goblet cell hyperplasia associated with a
productive NTHi infection. C. The middle ear of an animal infected with the wild type parent strain 86-028NP. The middle ear lumen is at the top of
each micrograph.
doi:10.1371/journal.pone.0091523.g004
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Chinchilla Model of Otitis Media
Because we noted a significant difference in the ability of the
DtoxAvapA mutant to survive during long-term co-culture in
human tissues, we performed challenge studies using the chinchilla
model of otitis media. For these assays, four animals (8 ears each)
were inoculated through the superior bullae with either the wild-
type strain or the DtoxAvapA mutant, with the same strain
inoculated into both ears. Four days after infection, the bullae
were opened and lavaged, and dilutions of the lavage fluid were
drop-plated onto chocolate agar plates and incubated for 24 hours
at 35uC in 5% CO2. Figure 2 shows a boxplot of the difference
between the recovery of the mutant versus the wild-type strain
during in vivo infection. Asterisks denote outliers, defined as 6
1.56the interquartile range [19]. Similar to the in vitro results, the
DtoxAvapA mutant displayed significantly diminished recovery
from the chinchilla middle ear, indicating that this TA locus
contributes to NTHi survival during infection.
Otoscopic images of the tympanic membrane of an animal
before (A) and 4 days after inoculation with the DtoxAvapA
mutant (B) are shown in Figure 3. Swelling and redness can be
observed around the membrane, suggesting inflammation. An
average of 1.56105 viable CFU/ml was obtained from a lavage of
this ear. To confirm a productive infection, the bulla of this animal
was step-sectioned and mounted onto slides. Images of hematox-
ylin-eosin (H&E)-stained sections of the middle ears of three
animals are shown in Figure 4. Note the characteristic goblet cell
hyperplasia and edema observed during NTHi infection (Dtox-
AvapA, 4B and wild type, 4C) compared to the uninfected control
animal (4A). This indicates that the DtoxAvapA mutant strain was
capable of producing an infection, even though it was less able to
survive in vivo than the wild-type parent.
Microarray Analysis
In order to identify any effects on the transcriptome of deleting
the toxAvapA TA locus in NTHi, we performed microarray
analysis on total RNA from both the wild-type and the mutant
strain grown in defined media to an OD600 of ,0.4. Interestingly,
we found a significant (defined as greater than 2-fold) reduction in
the transcription of the tryptophan biosynthesis regulon (Table 3).
We confirmed this microarray data by qPCR of NTHI1763
(trpCF), a key gene in the tryptophan biosynthesis pathway.
However, we did not observe significant differences between the
wild-type and mutant strains in the transcription of the trypto-
phanase and tryptophan permease genes tnaA and tnaB
(NTHI0831-0832), the tryptophanyl-tRNA synthetase trpS
(NTHI0755), the Trp operon repressor trpR (NTHI0996) or the
high-affinity tryptophan-specific transport protein gene mtr
(NTHI0396). This suggested that transcription of the biosynthetic
regulon was specifically affected. To further investigate these
results, we performed HPLC studies on conditioned medium of
both the wild-type and mutant strains to determine the levels of
tryptophan remaining in the media. All $2-fold differentially-
regulated genes identified in the DtoxAvapA mutant and their fold
changes are listed in Supplemental Table 1.
HPLC of Conditioned Medium
In Escherichia coli and in many other bacteria, the regulation of
the tryptophan biosynthetic operon is controlled in part by the
levels of available tryptophan in the organism [20]. Therefore, we
were interested in determining whether there were any differences
in the relative concentrations of tryptophan remaining in
conditioned medium between the wild-type and mutant strains.
If there were, this would suggest that the tryptophan regulon was
depressed due to an increased transport of tryptophan from the
medium into the mutant strain. To ascertain this, we performed
high performance liquid chromatography (HPLC) on samples of
conditioned defined medium from the wild-type and mutant
strains to compare the levels of tryptophan remaining in the
media. We grew both organisms in defined media to an OD600 of
,0.4, harvested the supernatant, pooled 3 biological replicates for
each strain and passed the media through a 3 kDa filter to remove
most of the larger protein and membrane components. The filtrate
was then derivatized with o-phthaldialdehyde/mercapto-ethanol
and run against an authentic tryptophan standard. Table 4 shows
that there was no significant difference between the levels of
tryptophan remaining in the supernatant of conditioned medium
from the wild-type or mutant strains.
Table 3. Fold decrease in transcription of the tryptophan
biosynthesis regulon in the NTHi DtoxAvapA mutant
compared to the wild-type strain.
Gene Fold Decrease Description
NTHI1701 2.591 Tryptophan synthase alpha chain; TrpA
NTHI1702 2.150 Tryptophan synthase beta chain; TrpB
NTHI1763 6.183 Tryptophan biosynthesis protein; TrpCF
NTHI1764 3.442 Anthranilate phosphoribosyltransferase; TrpD
NTHI1767 3.574 Glutamine amidotransferase; TrpG
NTHI1768 3.068 Anthranilate synthase component I; TrpE
doi:10.1371/journal.pone.0091523.t003
Table 4. HPLC results of the relative amounts of tryptophan
in derivatized samples of conditioned medium from the wild-
type or mutant NTHi strains.
Strain
Micrograms of tryptophan in sample
(±SD) p value
86-028NP 0.315 (0.003) .0.05
DtoxAvapA 0.365 (0.049) (not significant)
doi:10.1371/journal.pone.0091523.t004
Figure 5. Ribonuclease activity assays using purified ToxA and
VapA proteins. Eighteen pmol of ToxA, VapA and the positive control
RNase A were incubated at 37uC for one hour with 5 pmol of
RNaseAlert substrate. The fluorescence of the negative control (buffer
alone) was subtracted from each value. (n = 3, RFU = relative
fluorescence units).
doi:10.1371/journal.pone.0091523.g005
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These results indicate that the observed decrease in the
transcription of the tryptophan regulon in the DtoxAvapA mutant
was not due to increased transport of this amino acid into the
mutant strain. This is further supported by our findings that there
were no significant differences in the transcription of genes active
in the degradation or transport of tryptophan in the mutant as
compared to the wild-type strain. Since HigA antitoxin homo-
logues in other organisms have not been found to be involved in
the regulation of genes other than their own operons [21], it is not
clear why the NTHi DtoxAvapA mutation results in decreased
tryptophan regulon transcription.
RNase Activity Assays
To determine if the HigB homologue in NTHi could cleave free
RNA, we purified both the toxin (ToxA) and antitoxin (VapA)
proteins and subjected each to ribonuclease activity assays. This
assay consists of a commercially-available RNA substrate that has
a quencher on one end and a fluorophore (FAM) on the other
(RNaseAlertH, Integrated DNA Technologies, Coralville, IA
USA). The intact substrate is not fluorescent, but when cleaved
it emits a bright green fluorescence. The probe is a single RNA
moiety of a proprietary length and sequence. RNA cleavage is
monitored by fluorescence intensity measured on the fluorescein
channel (485 nm excitation, 520 nm emission) that increases over
time. Figure 5 shows the results of 5 pmol of substrate incubated at
37uC for one hour with 18 pmol of purified ToxA and VapA. The
negative control (protein renaturation buffer) was subtracted from
each value, and the positive control was 18 pmol of commercially-
available RNase A. To further characterize the ribonuclease
activity of ToxA, kinetic studies were performed in which the
concentration of the RNaseAlert substrate was increased while
keeping the concentration of ToxA in each reaction at 18 pmol.
Figure 6A illustrates the initial reaction progress in the first 6
minutes with increasing concentrations of substrate, while
Figure 6B shows the reaction approaching completion at 30.5
minutes (5 pmol RNaseAlert; 18 pmol ToxA).
The HigB toxin from P. vulgaris has been identified as having
ribonuclease activity on mRNA in the context of a ribosome at A-
rich sites in E. coli [22], and here we show that ToxA from NTHi
displays activity on RNA that is unbound in solution. This is
consistent with our previous results, in which we have shown that
two other TA loci toxins in NTHi, VapC-1 and VapD, are active
on free RNA in vitro [13,23]. Other studies have found that
induced ectopic expression of the HigB toxin in M. tuberculosis lead
to growth arrest and cell death as well as cleavage of tmRNA and
mRNA predominantly from genes regulated by the IdeR iron-
dependent repressor and the zinc uptake repressor Zur [24].
However, the HigB cleavage sites identified in the M. tuberculosis
tmRNA ssrA in that investigation were not particularly A-rich.
This suggests that there may be a broader range of RNA targets of
the HigB toxin homologues in different organisms than originally
thought. If this is true, the observed repression of the tryptophan
biosynthetic regulon in the DtoxAvapA strain might be due to the
loss of the native function of ToxA on other targets, rather than
directly on the regulon itself. Our data indicate that this loss does
not influence growth in defined media, but significantly impacts
NTHi survival during infection both in vitro and in vivo.
Conclusions
We show that deleting the toxAvapA locus results in attenuation
of NTHi survival during infection, both in vitro and in vivo. We
purified ToxA and identified it as having ribonuclease activity,
suggesting that the mechanism by which the toxAvapA TA locus
affects persistence is to facilitate a state of dormancy via mRNA
degradation. Unexpectedly, we found by microarray analysis that
deleting this locus also resulted in the repression of the tryptophan
biosynthetic regulon in the mutant strain. No significant difference
between the ability of the wild-type and mutant strains to take up
this amino acid from the media was identified. Further study is
warranted to determine the exact mechanism by which the
deletion of toxAvapA affects the regulation of this essential
metabolic pathway.
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